Modest Alcohol Consumption Will Not Protect Against Obesity, T2DM Risk
An investigation explored dose-dependent effects of alcohol consumption of type 2 diabetes mellitus and obesity risk.
An investigation explored dose-dependent effects of alcohol consumption of type 2 diabetes mellitus and obesity risk.
Researchers sought to characterize the clinical effect of obesity on defecation disorders, such as fecal incontinence or constipation.
Semaglutide is a GLP-1 receptor agonist.
A phase 3 clinical trial examined the efficacy of semaglutide 50 mg for treating overweight and obesity in adults without type 2 diabetes.
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Wegovy is a glucagon-like peptide-1 receptor agonist.
Highlights from National Lipid Association Scientific Sessions 2023 include metabolic syndrome, diabetes, HEAT assessment tool, and lifestyle interventions.
Researchers examined the safety and efficacy of several weight loss drugs approved for the management of obesity.
Latest findings are from a study of 36,756 men with universal access to PSA screening.
A meta-analysis examined the safety and efficacy of tirzepatide for weight loss in individuals with overweight or obesity.